Coxsackievirus B serotype 5 antigens (CVB5)

Coxsackievirus B serotype 5 (CVB5) is a significant human pathogen belonging to the Enterovirus B species within the Picornaviridae family. The antigens of CVB5, primarily the structural capsid proteins (VP1, VP2, VP3, and VP4) and non-structural proteins such as the 3C protease and 3D polymerase, serve as critical targets for the host immune system and pharmacological intervention (Source: NCBI Taxonomy, PubMed). CVB5 is a leading cause of aseptic meningitis outbreaks worldwide and is frequently associated with myocarditis, neonatal systemic illness, and hand-foot-and-mouth disease (Source: CDC, StatPearls). In the context of drug development, these antigens are targeted by experimental vaccines designed to elicit protective neutralizing antibodies or by small-molecule antivirals that disrupt the viral life cycle (Source: Journal of Virology). For instance, capsid-binding inhibitors like pleconaril have been investigated for their ability to prevent viral attachment and uncoating by interacting with the hydrophobic pocket of the VP1 protein (Source: PubMed). While no CVB5-specific antiviral is currently FDA-approved, these antigens remain focal points for diagnostic assay development and the engineering of broad-spectrum enterovirus inhibitors (Source: UniProt).

Other names

Coxsackievirus B5CV-B5Enterovirus B5Coxsackie B5 virusCVB5 capsid proteinsCVB5 VP1 protein

Inhibition of viral uncoating through capsid binding; inhibition of viral 3C protease to prevent polyprotein cleavage; inhibition of viral RNA-dependent RNA polymerase; induction of neutralizing antibodies via vaccination.